Boron-albumin conjugates are promising anti-cancer therapeutics as they can be administered less frequently than alternative therapeutic agents and yet offer sufficient accumulation of the action component at the tumor site, which can improve the quality of life for cancer patients. The gene discussed is ALB; the disease is cancer.